KOD - Kodiak says Phase 3 trial for lead asset met key goals
2023-11-06 07:00:44 ET
More on Kodiak Sciences
- Kodiak's Uncertain Path: Reallocating The Cash Reserve (Rating Downgrade)
- Kodiak Sciences CMO resigns following failed Phase 3 studies for lead drug
- Seeking Alpha’s Quant Rating on Kodiak Sciences
- Historical earnings data for Kodiak Sciences
- Financial information for Kodiak Sciences
For further details see:
Kodiak says Phase 3 trial for lead asset met key goals